Art

J-GLOBAL ID：201602220804103301   Reference number：16A0711756

Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size

急性非代償性心不全患者におけるトルバプタン治療に対する反応者の臨床的特徴:保存された腎臓の大きさの重要性

Author (21)： Toda Hironobu (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Toda Hironobu (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Nakamura Kazufumi (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Nakahama Makoto (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Wada Tadashi (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Wada Tadashi (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Watanabe Atsuyuki (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Watanabe Atsuyuki (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Hashimoto Katsushi (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Hashimoto Katsushi (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Terasaka Ritsuko (Department of Cardiology, Fukuyama City Hospital, Fukuyama, Japan) ,  Tokioka Koji (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Nishii Nobuhiro (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Miyoshi Toru (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Kohno Kunihisa (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) ,  Kawai Yusuke (Department of Cardiology, Ehime Prefectural Central Hospital, Ehime, Japan) ,  Miyaji Kohei (Department of Clinical Science, National Hospital Organization Okayama Medical Center, Okayama, Japan) ,  Koide Yuji (Department of Cardiovascular Medicine, Mitoyo General Hospital, Kagawa, Japan) ,  Tachibana Motomi (Department of Cardiology, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan) ,  Yoshioka Ryo (Department of Cardiology, Sakakibara Heart Institute of Okayama, Okayama, Japan) ,  Ito Hiroshi (Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan)
Material： Journal of Cardiology  (J Cardiol)
Volume： 67  Issue： 2  Page： 177-183  Publication year： Feb. 2016 
JST Material Number： W2218A  ISSN： 0914-5087  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： *cardiac insufficiency ,...
Semi thesaurus term： *acute decompensated heart failure ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A0711756&from=J-GLOBAL&jstjournalNo=W2218A") }}

Author keywords (3)： Heart failure ,  Vasopressin ,  Kidney size

JST classification (3)： Drug therapy(=pharmacotherapy)for urogenital diseases  (GM05020V) ,  Clinical application of drugs acting on urinary system  (GW11020C) ,  Urologenital system diagnosis  (GM02000E)

Substance index (1)： OPC-41061

Reference (22)：

• JCS-Joint-Working-Group. Guidelines for treatment of acute heart failure (JCS 2011). Circ J 2013;77:2157-201.
• Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690-6.
• Gheorghiade M, Konstam MA, Burnett Jr JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. J Am Med Assoc 2007;297:1332-43.
• Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011;25(Suppl. 1):S57-65.
• Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, Sugiura E, Kumagai N, Nakamori S, Nakajima H, Hoshino K, Machida H, Okamoto S, Onishi K, Nakamura M, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 2012;60:462-9.

Terms in the title (9)： 急性非代償性心不全 ,  患者 ,  トルバプタン ,  治療 ,  臨床 ,  保存 ,  腎臓 ,  大きさ ,  重要性